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Abstract: 
 
Objectives: We sought to identify the proportion of systematic reviews of 
adverse effects which search for unpublished data and the success rates of 
identifying unpublished data for inclusion in a systematic review. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Study Design and Setting: Two reviewers independently screened all records 
published in 2014 in the Database of Abstracts of Reviews of Effects (DARE) 
for systematic reviews where the primary aim was to evaluate an adverse effect 
or effects. Data were extracted on the types of adverse effects and interventions 
evaluated, sources searched, how many unpublished studies were included and 
source or type of unpublished data included. 
Results: From 9129 DARE abstracts, 348 met our inclusion criteria. Most of 
these reviews evaluated a drug intervention (237/348, 68%) with specified 
adverse effects (250/348, 72%). Over a third (136/348, 39%) of all the reviews 
searched a specific source for unpublished data, such as conference abstracts or 
trial registries and nearly half of these reviews (65/136, 48%) included 
unpublished data. An additional 13 reviews included unpublished data despite 
not searching specific sources for unpublished studies. Overall, 22% (78/348) of 
reviews included unpublished data/studies. 
Conclusion: The majority of reviews of adverse effects do not search 
specifically for unpublished data but, of those that do, nearly half are successful. 
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Abstract 
Objectives: We sought to identify the proportion of systematic reviews of adverse effects 
which search for unpublished data and the success rates of identifying unpublished data for 
inclusion in a systematic review. 
Study Design and Setting: Two reviewers independently screened all records published in 
2014 in the Database of Abstracts of Reviews of Effects (DARE) for systematic reviews 
where the primary aim was to evaluate an adverse effect or effects. Data were extracted on 
the types of adverse effects and interventions evaluated, sources searched, how many 
unpublished studies were included and source or type of unpublished data included. 
Results: From 9129 DARE abstracts, 348 met our inclusion criteria. Most of these reviews 
evaluated a drug intervention (237/348, 68%) with specified adverse effects (250/348, 72%). 
Over a third (136/348, 39%) of all the reviews searched a specific source for unpublished 
data, such as conference abstracts or trial registries and nearly half of these reviews (65/136, 
48%) included unpublished data. An additional 13 reviews included unpublished data despite 
not searching specific sources for unpublished studies. Overall, 22% (78/348) of reviews 
included unpublished data/studies. 
Conclusion: The majority of reviews of adverse effects do not search specifically for 
unpublished data but, of those that do, nearly half are successful. 
 
Keywords: Adverse effects, systematic review, unpublished data, grey literature, trial 
registry, information retrieval 
 
What is new? 
• 39% of systematic reviews of adverse effects specifically search for unpublished data 
• 22% of systematic reviews of adverse effects include unpublished data 
• The most popular sources searched for unpublished data are conference 
scanning/databases, contacting authors or searching ClinicalTrials.gov 
• The success rate of searching in specific sources for unpublished data ranged from 0% 
to 36% with conference abstract searches being most successful. 
• We need more research into the most effective sources for searching for unpublished 
data 
Most systematic reviews of adverse effects do not include unpublished 
data 
 
Introduction 
Adverse effects are harmful or undesirable outcomes that occur during or after the use of a 
drug or intervention, for which there is at least a reasonable possibility of a causal relation 
(1). Information on the adverse effects of healthcare interventions is important for decision-
making by regulators, policy makers, healthcare professionals and patients. Serious or 
important adverse effects may occur rarely and as such systematic reviews and meta-analyses 
that synthesize harms data from numerous sources (potentially involving both published and 
unpublished datasets) can provide useful insights. However, because adverse effects data are 
poorly reported in published clinical trials (2-9), systematic reviews of adverse effects may be 
incomplete if they rely on peer reviewed journal publications alone, or if the reviewers 
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conduct only a relatively limited search for unpublished sources.  
A consensus on a clear definition of ‘published’ and ‘unpublished’ data is difficult to reach. 
For practical reasons, and to maintain consistency with our previous research work,(10) 
‘published’ will refer to peer reviewed journal articles and ‘unpublished’ data will refer to all 
other material. It is acknowledged, however, that unpublished data can be publically available 
(for example, through web registries or regulatory agencies)) but these do not undergo the 
processes of peer-reviewing, editing, formatting and document identification that are part and 
parcel of established journal publications. 
 
Serious concerns have emerged regarding publication bias or selective omission of outcomes 
data whereby negative results are less likely to be published than positive results and where 
adverse effects are underreported (11). One way to attempt to overcome these biases is to 
include unpublished studies or data. Current guidance for all types of systematic reviews 
(irrespective of outcome) recommends searching unpublished sources (12-14) such as 
contacting authors or manufacturers, seeking conference abstracts and searching trial 
registries (including industry trial registries). For reviews of adverse effects the Cochrane 
Handbook also recommends searching regulatory authorities websites such as the US Food 
and Drug Administration (FDA), the Medicines & Healthcare products Regulatory Agency 
(MHRA) and the European Medicines Agency (EMA)(12). Such guidance may have led to 
more systematic reviewers searching for unpublished data. 
 
Nevertheless, previous research of systematic reviews of adverse effects from 1994 to 2011 
has indicated that, few attempts are made to search for unpublished data or industry funded 
data (10, 15). This may be due to an expected low return or the difficulties of searching for 
unpublished data or in obtaining and incorporating unpublished data into systematic reviews 
(16) or a concern that unpublished data is not peer reviewed. In addition, it is unknown 
whether this situation is improving.  
 
In contrast, research has indicated that much of the data on adverse effects are unpublished 
accounting for between 43%-100% of the number of adverse effects and also a wider range 
of types of adverse effects are reported in the unpublished literature (9, 17-25). A 
considerable amount of otherwise ‘missing’ adverse effects data therefore may potentially be 
retrieved from a diverse range of other sources such as trial registries, regulatory agencies or 
authors. This has particularly important implications for evaluations of adverse effects 
because conclusions based on only published studies may not present a true picture of the 
adverse effects. 
 
A lack of searching for and identification of unpublished data may pose serious threats to the 
validity of systematic reviews of adverse effects. Yet little is known as to whether 1) 
systematic reviewers fail to search for unpublished data or 2) whether they fail to identify 
unpublished data when they search and 3) which data sources are most fruitful for searching 
for unpublished data. Hence, we aimed to estimate the extent to which unpublished data is 
sought and identified within systematic reviews of adverse effects by carrying out a 
retrospective analysis of systematic reviews published in 2014. 
 
Methods 
Search strategy  
Systematic reviews of adverse effects were identified by screening all records published in 
2014 in the Database of Abstracts of Reviews of Effects (DARE) (via the Centre for Reviews 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
and Dissemination (CRD) website, April 2015). No search strategy was implemented, as 
previous research has indicated that even very broad search strings would miss relevant 
records (26). The DARE database was chosen because it was the most accessible major 
collection of systematic reviews of healthcare interventions. DARE was compiled through 
rigorous monthly searches of bibliographic databases, including MEDLINE and EMBASE, 
as well as handsearching of key journals, grey literature, and regular searches of the Internet. 
It also contains all Cochrane reviews, both new and updated. DARE ceased production in 
March 2015 but continues to be available in archive format. 
 
Inclusion/exclusion criteria  
A review was included if the primary aim was to evaluate an adverse effect or effects, known 
to be, or suspected to be, associated with an intervention, regardless of whether the review 
author's hypothesis or conclusions stated that the intervention increased the outcome. Articles 
that investigated the complete safety profile of an intervention were included if this was their 
primary aim. The author and another researcher independently screened titles and abstracts 
and selected full articles for inclusion. Any discrepancies between the researchers were 
resolved by discussion and consensus.  
 
Data extraction 
Pre-defined descriptive data on review methodology were abstracted using a standardised 
form created in Microsoft Access 2010. For each review, baseline data were collected on: the 
types of intervention (for example, drug intervention, diagnostic procedure or surgical 
technique); and the type of adverse effects evaluated (for example, pre-specified named 
adverse effects or generic adverse effects).  
 
Details were extracted on how information on adverse effects was retrieved by the authors of 
the reviews, namely:  
• Which bibliographic databases were searched, for example, MEDLINE or Embase. 
• Other sources of information consulted or additional approaches to information 
gathering employed, for example, reference checking, handsearching, or contacting 
authors.  
• Whether any sources specifically containing only unpublished data were searched 
such as conference abstracts or trial registries. 
• Whether any sources that contain some unpublished references in addition to 
published articles were searched, such as Embase (which contains conference 
abstracts in addition to published journal articles), Cochrane CENTRAL (which 
contains records identified from multiple sources including conferences, 
handsearching and contacting experts as well as records from MEDLINE and 
Embase) or reference lists from published articles (which can be compiled by multiple 
methods). 
 
In addition we extracted data on whether unpublished data were included in the systematic 
review and if so 
• How many included references were unpublished and what proportion of the total 
number of included references this represented. 
• For how many published articles were additional unpublished data retrieved (for 
example from authors of the published article or from trial registries or industry). 
• What type of unpublished data were included (such as conference abstracts, trial 
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registry data, or data from manufacturers or authors).  
• Where indicated by the review authors we also extracted the source of each 
unpublished study. 
 
We checked the abstract, figures (particularly the flow diagrams), appendices and reference 
lists of the systematic reviews as well as the full text for an explanation as to the sources 
searched and the publication status of included studies. 
 
Analysis 
Data were categorized and a descriptive summary presented. Although our primary aim was 
to assess the level of unpublished data searched for and used in systematic reviews of adverse 
effects, we could also analyse some time trends with respect to the sources searched. The 
results were compared, where possible, with a previous  survey on the retrieval of 
information for systematic reviews of adverse effects (27, 28). In the previous survey, data 
were collected on a range of aspects related to the retrieval of information including the 
sources/databases searched. Similar methods were used in the previous survey as the current 
survey including the same Access database, same definition of published versus unpublished, 
and the same authors conducting the data extraction. This comparison may give some 
indication as to whether specific sources for unpublished data are increasingly searched in 
systematic reviews of adverse effects. 
 
Results 
From 9129 DARE abstracts screened, 451 full reports were retrieved and 348 reviews met the 
inclusion criteria. Overall 4% (348/9129) of reviews in DARE with a publication date of 
2014 focused on adverse effects.  
 
Scope of adverse effects evaluation  
The majority of the reviews concentrate on pre-specified adverse effect outcomes (such as 
thrombosis or stroke) (198/348, 57%) or a pre-specified class of effects (such as 
gastrointestinal or cardiovascular) (52/348, 15%), rather than analysing all potential adverse 
effects for a given intervention (98/348, 28%).  
Types of interventions studied  
The included reviews are predominantly those evaluating the adverse effects of drugs 
(237/348, 68%) followed by those evaluating surgical or dental procedures (83/348, 24%). 
Only a few studies (31/348, 9%) examine physical or device interventions, such as 
acupuncture, tai chi or hearing aids, and fewer still examine diagnostic/screening 
interventions (6/348, 2%) (some reviews evaluate more than one type of intervention). The 
most common interventions studied are, corticosteroids (11 reviews), statins (9 reviews), and 
non-steroidal anti-inflammatory drugs (NSAIDs) (6 reviews). 
Bibliographic databases and other sources searched  
Nearly all of the reviews (345/348, 99%) list the resources used to identify the primary 
studies for the review. Only three reviews do not report on the search methods used. 
 
The median number of bibliographic databases searched is three (range 1 to 16). 24/348 
reviews (7%) search one database and in all but one case this is MEDLINE. Around a quarter 
of the reviews search two or fewer bibliographic databases (91/348, 26%). A previous survey 
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of reviews published from 1994 to 2011 found that 20% of reviews of adverse effects search 
one database and that 43% searched two or fewer bibliographic databases (27, 28) . This 
indicates a trend towards fewer reviews restricting their search to a small number of 
bibliographic databases. In the current survey (as with the previous survey) the most 
frequently searched database is MEDLINE (342/348, 98%), followed by Embase (235/348, 
68%). 
 
Many reviews report searching at least one source other than bibliographic databases. The 
median number of other sources searched is one (range 0 to 5). Reference lists are by far the 
most popular non-database resource (268/348, 77%) (Table 1). 
 
Searching for unpublished data 
Over a third (136/348, 39%) of all the reviews searched at least one specific source for 
unpublished data, such as conference databases or trial registries (Table 1).  Table 1 also 
compares the percentage of reviews that search each data source and demonstrates that many 
unpublished sources have not increased in popularity for systematic reviewers of adverse 
effects with the exception of ClinicalTrials.gov (3% to 12%) and conference abstract searches 
(17% to 20%). In fact some sources of unpublished data have decreased in popularity 
including contacting authors (18% to 14%) and industry/industry trial registers (13% to 5%). 
 
The majority of the reviews (334/348, 96%) searched at least one source that contained 
unpublished data in addition to published journal articles. These sources included databases 
such as CENTRAL, Embase, or Google Scholar (Table 1). Only four reviews limited their 
search to sources which contained no unpublished data whatsoever. Six reviews only search 
specific sources of unpublished data (such as ClinicalTrials.gov or conference sources) and 
three reviews do not report on the sources searched. Within those sources which contain both 
published and unpublished data the Internet (4% to 9%), Google Scholar (2% to 8%), Scopus 
(2% to 9%) and Embase (54% to 68%) are becoming increasingly popular sources to search 
(Table 1). 
 
>> Insert Table 1: Sources with unpublished data searched compared to previous survey<< 
 
Inclusion of unpublished data 
Whilst 78 reviews (22%) include studies that are unpublished or make use of unpublished 
data in their analysis, 258 reviews (74%) include only published articles from peer-reviewed 
journals and 12 reviews (3%) do not list or describe the included studies (Figure 1). Of the 
different types of interventions, drug intervention reviews are most likely to include 
unpublished data with 28% of all drug intervention reviews including unpublished data 
(Table 2). This is followed by reviews of physical or device interventions (13%) and reviews 
of surgical or dental procedures (10%) (Table 2). 
 
>> Insert Table 2: Types of interventions studied and inclusion of unpublished data<< 
 
Number of unpublished studies or data included 
Of the 78 systematic reviews which include unpublished studies or unpublished data, 64 
included at least one unpublished study with no corresponding published version and 24 
included unpublished data in addition to published data for the same study at least once 
(some reviews had both) (Figure 1). 
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>> Insert Figure 1: Flow diagram of systematic reviews <<  
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Reviews including unpublished studies (without corresponding publications) 
Within the 64 reviews which included at least one unpublished study (without a 
corresponding publication), the number of unpublished studies included in each review varied 
from 1 to 56 studies with a median of 2 (mean of 5). The total number of included studies in 
each of the 64 reviews varied from 5 to 157 studies with a median of 23 (mean of 29). As we 
had the numbers of both the included unpublished studies and the total number of studies 
included, we could calculate the percentage of included papers in each review that were 
unpublished. A median of 13% (mean of 17%) of the included studies in each review were 
unpublished (range 1% to 100%). 
 
The types of unpublished studies included in the reviews varied. Many reviews included 
more than one unpublished study from the same source. The highest number of unpublished 
records included in total from the reviews were from ClinicalTrials.gov, followed by 
conference journal abstracts and conference proceedings (Figure 2). 
 
>> Insert Figure 2: Number of included unpublished studies from each source << 
 
Unpublished Data (in addition to published data) 
Of the 24 reviews which obtained additional unpublished data for published articles, 19 
reviews gained additional unpublished data from the authors of published articles 3 reviews 
gained additional information to the publications from conference abstracts, and 3 gained 
additional information to the publications from ClinicalTrials.gov (some reviews gained 
additional unpublished data from more than one source). 
 
Success rates of searching for unpublished data 
Overall of the 136 reviews that specifically searched for unpublished data, 65 included 
unpublished data, 66 included only peer reviewed journal articles and 5 did not give any 
details of the included studies. This indicates a successful search rate of nearly half (48%, 
65/136). However, the majority of reviews that searched for unpublished data used more than 
one source and each source had a varying success rate. 
 
Where possible the source of the unpublished studies or data were recorded. Table 3 indicates 
that the most successful sources for unpublished data are scanning conferences (36%), 
Proquest Dissertation and Theses (33%) (based on only 3 reviews), contacting 
experts/authors (31%), ClinicalTrials.gov (29%) and the US Food and Drug Administration 
(FDA) website (29%). Many of these figures, however, will be under estimates as not all the 
reviews indicated where the included studies were obtained.  
 
>>Table 3: Success rates of searching individual sources<< 
 
Whilst 65 of the 136 reviews which searched specifically for unpublished data included 
unpublished data, in total 78 reviews included unpublished data. There were therefore 13 
reviews which included unpublished studies in their analysis but did not report searching a 
specific source of unpublished data. These 13 reviews may not have reported their searches 
fully or may have identified unpublished data from sources which are not specific to 
unpublished data (e.g. checking reference lists). In actuality, of these 13 reviews, 9 included 
conference abstracts (identified from reference checking, Google Scholar and CENTRAL or 
source not reported), one a dissertation (source not reported), one a record from 
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ClinicalTrials.gov (source not reported but does not state that ClinicalTrials.gov was 
searched) and one a record from current controlled trials.com (again source not reported and 
does not state that Current Controlled Trials.com was searched).. For the majority of the 13 
reviews, therefore, it was not stated where the included unpublished studies were obtained 
but it is likely that deficiencies in the reporting of searches are leading to the underreporting 
of unpublished data sources searched. 
 
Limitations 
The number of reviews searching for or including unpublished data can only be estimated in 
this study due to poor reporting in the systematic reviews. For instance, few reviewers stated 
the results of contacting authors or industry and whether further data were obtained and at 
least two reviews searched unpublished data sources (ClinicalTrials.gov and current 
controlled trials.com) without listing these sources in the methods section.   
 
There is also a tendency to search the traditional bibliographic databases such as MEDLINE 
and Embase first. There may have been instances, therefore, where although no new studies 
were identified from searching data sources such as ClinicalTrials.gov, scanning conferences 
or reference checking, the same studies were identified. In these instances the duplicate 
studies may not have been recorded.  
 
In addition, unpublished data may have contributed to the review by providing information 
on ongoing studies, useful background information or by informing the search process. The 
value of unpublished data to the systematic review overall, however, was not measurable. 
 
Discussion 
39% (136/348) of systematic reviews of adverse effects published in 2014 searched at least 
one source of unpublished studies (such as conference abstract databases or trial registries). 
Encouragingly nearly half of these reviews (65/136, 48%) were successful in identifying and 
including an unpublished study or unpublished data.  
 
The overall proportion of all systematic reviews of adverse effects including unpublished data 
or studies, however, remains low at just over a fifth (22%, 78/348). This is due to a 
combination of reviewers not searching for unpublished data and searches being 
unsuccessful.  
 
The number of systematic reviews assessing harms has been growing rapidly over the past 
five years. The Database of Abstracts of Reviews of Effects (DARE) includes 104 reviews of 
adverse effects published in 2010 and 348 in 2014.(26) However, this increase is in line with 
the overall trend of numbers of systematic reviews being published, such that the proportion 
of total reviews of adverse effects from DARE has remained relatively stable.  
 
Overall there has been an increase in 2014 in those systematic reviews of adverse effects 
focusing on non-drug interventions as compared to reviews published between 1994 and 
2011. The proportion of reviews which examined surgical or dental procedures rose from 
13% to 24%, those examining physical interventions rose from 7% to 9%, and diagnostic or 
screening interventions rose from 1% to 2%. 
 
The number of sources and the number of databases searched has increased since 1994. The 
reviews in this survey were more likely to search more sources than reviews published 
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between 1994 and 2010. In particular, searching of Embase (54% to 67%), ClincialTrials.Gov 
(3% to 11%) and the Google Scholar (2% to 8%) or a general Internet search (0% to 9%) 
have all risen. 
 
It is encouraging to note that, in line with current guidance (12-14) , some systematic 
reviewers are increasingly searching more widely to include unpublished sources, such as 
conferences, and trial registries. However, the proportion of reviews conducting specifc 
searches for unpublished data (39%) or including unpublished data remains low (22%) and 
worryingly the use of some sources for unpublished data such as industry and authors has 
declined. While we have used a very inclusive definition of ‘unpublished’ if a narrower 
definition were adopted (such as not in the public domain) then the proportion of reviews 
including unpublished data would have been much smaller at 19/348 (5%). In addition some 
reviews still have inclusion criteria that purposefully excludes unpublished material such as 
the requirement that the study needs to be published in peer-review journal or to not be a 
conference abstract. This is despite empirical data suggesting that conclusions of systematic 
reviews can change when unpublished data are used. A classic example is the review of 
reboxetine, where publication bias has been clearly demonstrated (29, 30) 
 
Although some systematic reviewers in this cohort contacted manufacturers, the decline in 
reviewers contacting manufacturers is of great concern and requires research into the reasons. 
This may ironically be a result of the recent publicity on the difficulties experienced by 
reviewers when attempting to obtain unpublished data from manufacturers (31) and the very 
long delays before a response is received (32), or with such small numbers may not be an 
overall trend. 
 
Clinical Study Reports (CSRs) are increasingly being discussed as an important source of 
data for adverse events in systematic reviews that are not available elsewhere (including 
published articles or publically available unpublished studies)(20, 33-36). Starting from 
September 2016 the European Medicines Agency (EMA) intends to provide access to clinical 
trial data - 60 days after a decision on an application for approval of a new drug has been 
made. Access will be made available via the EMA website, either on screen after a 
registration process or will be downloadable for identified users without the need for 
Freedom of Information requests. The changes at the EMA will certainly make it easier for 
systematic reviewers to access data on clinical trials carried out by pharmaceutical 
companies. This could lead to a major change in the sources used in systematic reviews of 
drug interventions, making systematic reviews less prone to publication and reporting bias 
(37). None of the 348 reviews in the current study reported using Clinical Study Reports 
(CSRs), even though 237 included drug interventions.  
 
We recognize that systematic reviewers may face constraints on time or resources, and there 
may be an additional burden in searching for unpublished sources. Doshi and Jefferson 
reported that whilst half of their Freedom of Information requests to the European Medicines 
Agency (EMA) were fulfilled within 9 weeks, the remaining half took between 15 and 58 
weeks before receipt of any data (32). The authors also remarked on the substantial amount of 
correspondence engaged with the regulators, particularly because of the absence of a publicly 
available or searchable list of holdings according to drug compounds. There may be similar 
delays in obtaining data from industry sponsors, with complaints regarding opacity of the 
process and lack of clear transparent criteria for granting or withholding access (31). 
Although access to clinical data from the EMA is set to change, at the time these reviews 
were conducted it was far easier for systematic reviewers to access trial registries (such as 
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clinicaltrials.gov) or regulatory authority websites, but major limitations include the lack of 
indexing terms or systematic, validated search strategies, as well as the potentially low yield 
because only 13.4% of trials report results within a year of study completion (38). 
 
Overall, of those reviews which searched specifically for unpublished data just under 50% 
were able to subsequently include additional data. This suggests that the exercise may not be 
entirely fruitless, and the benefits of searching for unpublished adverse effects data 
potentially outweighs the time or costs involved. However, there appears to be wide variation 
between the sources searched. In particular, scanning conferences, contacting authors, 
searching trial registries, searching the FDA website appears most fruitful in terms of 
identifying at least one relevant study whereas scanning conferences and searching 
ClinicalTrials.gov appears most fruitful in terms of identifying a larger volume of records 
(Figure 2) 
 
The disappointingly low proportion of reviews including unpublished data may be a result of 
a combination of limited search approaches and variable success rates of searching. Further 
research examining the success rates of exhaustive searching for unpublished data would be 
useful to ascertain whether important data could be found and if so where. There needs to be 
a new focus on developing access to unpublished adverse effects data, rather than the current 
restrictive model. Ease of access to adverse effects data and greater transparency of reporting 
will help reviewers move away from complicated, onerous searches that have an 
uncomfortably low yield. This will encourage systematic reviewers to search more widely as 
guidance suggests.  
 
Overall the current situation within systematic reviews of adverse effects could be 
substantially improved. One way to achieve this would be to reduce the barriers and improve 
accessibility to unpublished data. Another would be to ensure that trial registries have 
updated results summaries, unlike the current situation where results are not made available 
despite completion of the trial (38-41). In addition, systematic reviewers need guidance and 
training on the most effective means to access unpublished data and the most useful data 
sources in terms of yield. 
 
Conclusions 
The majority of reviews of adverse effects do not search specifically for unpublished data 
but, of those that do, nearly half are successful. Given the potential for publication and 
outcome reporting bias, easier access and greater transparency in reporting of adverse effects 
data is urgently required, and more reviews should make efforts to identify such unpublished 
data.  
 
We also need detailed guidance on the most useful sources to search for unpublished adverse 
effects data. Further research, therefore, to uncover the most successful sources of 
unpublished data should be a priority. 
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Table 1: Sources with unpublished data searched compared to previous survey 
 
Data sources Previous survey 1994-2011 
(849 reviews) 
Current survey 2014 
(348 reviews) 
 
Source of unpublished data 
Scanned conferences or searched CPCI  17% (142) 20% (70) 
Contacted experts/authors 18% (156) 14% (50) 
ClinicalTrials.gov 3% (25) 12% (42) 
Food and Drug Administration (FDA) 
website 
6% (47) 5% (17) 
Contacted industry or Industry trial 
register or website 
13% (110) 5% (19) 
Manufacturers Package Insert 2% (13) 3% (11) 
European regulatory agencies (including 
MHRA and EMA) 
0%  3% (9) 
Current controlled trials.gov 1% (12) 2% (8) 
International Clinical Trials Registry 
Platform (ICTRP)  
0.35% (3) 1% (5) 
Health Technology Assessment (HTA) 
Database 
1% (11) 1% (4) 
Proquest Dissertation and Theses  2% (16) 1% (3) 
metaRegister of Controlled Trials (mRCT) 0% 1% (3) 
Any source of unpublished data  39% (136) 
 
Sources which include published and unpublished data 
Reference lists of published studies 76% (642) 77% (268) 
Embase 54% (462) 68% (235) 
CENTRAL 24% (205) 28% (98) 
CINAHL 13% (107) 11% (37) 
General Internet Search 4% (34) 9% (32) 
Scopus 2% (21) 9% (32) 
Google Scholar 2% (15) 8% (27) 
Database of Abstracts of Reviews of 
Effects (DARE) 
6% (48) 4% (14) 
Science Citation Index (SCI)* 5% (45) 3% (9) 
LILACS 3% (25) 2% (7) 
Citation search 0% 2% (7) 
TOXLINE 2% (17) 1% (5) 
Related citations  1% (10) 1% (5) 
Any source of published and unpublished 
data 
 96% (334) 
NB Sources searched in three reviews or fewer in the current survey are excluded.  
*Science Citation Index is likely to be search in more reviews as it is often referred to as Web of Science 
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Table 2: Types of interventions studied and inclusion of unpublished data 
Type of intervention and 
number of reviews 
Includes unpublished 
data (n=78) 
Includes only peer-
reviewed journal 
articles (n=258) 
Included studies 
not reported 
(n=12) 
Drug interventions (n=237) 28% (67) 68% (161) 4% (9) 
Surgical or dental 
procedures (n=83) 
10% (8) 87% (72) 4% (3) 
Physical or device 
interventions (n=31) 
13% (4) 81% (25) 6% (2) 
Diagnostic/screening 
interventions (n=6) 
0 (0%) 100% (6) 0 (0%) 
Other (n=8) 0 (0%) 100% (8) 0 (0%) 
NB: Many reviews included more than one type of intervention 
 
Table 3: Success rates of searching individual sources 
 
Source and number of reviews Identified unpublished data for inclusion 
from source* 
Scanned conferences or searched CPCI (n=70) 36% (25) 
Proquest Dissertation and Theses (n=3) 33% (1) 
Contacted experts/authors (n=50) 39% (19) 
ClinicalTrials.gov (n=42) 29% (12) 
Food and Drug Administration (FDA) (n=17) 29% (5) 
Industry trial register or website or contacted 
industry (n=15) 
20% (3) 
International Clinical Trials Registry Platform 
(ICTRP) (n=5) 
20% (1) 
Current controlled trials.gov (n=8)  13% (1) 
European regulatory agencies (including MHRA and 
EMA) (n=9) 
11% (1) 
Health Technology Assessment (HTA) Database 
(n=4) 
0 (0%) 
Manufacturers Package Insert (n=11) 0 (0%) 
metaRegister of Controlled Trials (mRCT) (n=3) 0 (0%) 
Any review that searched a specific unpublished data 
source (n=136) 
48% (65) 
 
*Likely to be underestimated as not always clear where included studies identified. 
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Figure 1: Flow diagram of systematic reviews 
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Figure 2: Number of included unpublished studies from each source  
 
 
 
 
 
0
20
40
60
80
100
120
140
160
Number of unpublished
studies from each source
0
20
40
60
80
100
120
140
160
